5 not yet recruiting, 5 recruiting, 5 terminated, 4 completed. 24 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Acute-On-Chronic Liver Failure: new trials by email Literature Review of Acute-On-Chronic Liver Failure trials Research Report on Acute-On-Chronic Liver Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial ucMSC and Standard medical treatment, Standard medical treatment - Acute-On-Chronic Liver Failure | Phase 2 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2027-01-01 | 2025-08-20 |
| RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver) - Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE) | Phase 1 / Phase 2 | Not yet recruiting | eGenesis, INC | 20 | 2026-10-01 | 2026-09-21 |
| Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure NTZ 500mg BID on top of SOC - Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure | Phase 2 | Not yet recruiting | Genfit | 16 | 2026-10-01 | 2026-07-09 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients AS1501 for injection - Acute-On-Chronic Liver Failure | Phase 2 | Recruiting | Shenzhen Third People's Hospital | 96 | 2026-06-15 | 2026-07-17 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF Low-dose experimental group, High-dose experimental group, Low-dose placebo control group - Acute-On-Chronic Liver Failure | Phase 2 / Phase 3 | Not yet recruiting | National Engineering Center of Cell Products | 96 | 2025-04-15 | 2025-03-19 |
| Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed Terlipressin Injectable Product - Acute on Chronic Liver Failure | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 60 | 2025-02-10 | 2025-02-07 |
| A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). Human albumin, Enoxaparin, Standard medical treatment - Liver Cirrhosis, Decompensated Cirrhosis of Liver | Phase 2 | Recruiting | European Foundation for Study of Chronic Liver Failure | 90 | 2024-07-01 | 2026-09-11 |
| Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure standard medical treatment, Placebo, hUC-MSC - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Recruiting | Beijing 302 Hospital | 150 | 2023-09-30 | 2024-05-07 |
| The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure MSC-EVs - Acute-On-Chronic Liver Failure, Acute Liver Failure | Phase 1 / Phase 2 | Withdrawn | Third Affiliated Hospital, Sun Yat-Sen University | 2023-09-01 | 2023-10-12 | |
| Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites | Phase 2 | Terminated | Genfit | 15 | 2023-07-02 | 2026-07-23 |
| F573 for Injection for the Treatment of Liver Injury/Failure F573 for injection, Sterilizing water for injection - Acute Liver Failure, Acute-On-Chronic Liver Failure | Phase 2 | Recruiting | Beijing Continent Pharmaceutical Co, Ltd. | 97 | 2023-03-24 | 2025-11-19 |
| Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose) - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Completed | GuangZhou Cellgenes Biotechnology Co., Ltd. | 100 | 2023-03-01 | 2026-10-21 |
| Safety of UC-MSC Transfusion for ACLF Patients Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) - Acute-On-Chronic Liver Failure | Phase 2 | Unknown | Hai Li | 16 | 2021-09-30 | 2021-07-21 |
| TAK-242 in Patients With Acute Alcoholic Hepatitis TAK-242, Placebo - Acute-On-Chronic Liver Failure | Phase 2 | Terminated | Akaza Bioscience Ltd | 4 | 2020-11-12 | 2026-10-14 |
| Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) HepaStem, Placebo - Acute on Chronic Liver Failure | Phase 2 | Terminated | Cellaion SA | 133 | 2020-01-21 | 2024-05-22 |
| Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Mesenchymal Stem Cell - Liver Failure, Acute on Chronic | Phase 1 / Phase 2 | Unknown | Tianjin Weikai Bioeng., Ltd. | 45 | 2019-10-01 | 2019-03-20 |
| Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients LifeLiver - Acute Liver Failure, Acute-On-Chronic Liver Failure | Phase 2 | Unknown | HLB Cell Co., Ltd. | 40 | 2019-03-29 | 2020-04-28 |
| Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure allo-APZ2-ACLF - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Terminated | RHEACELL GmbH & Co. KG | 5 | 2019-03-22 | 2021-11-17 |
Showing 20 of 24. Sign in to see all of them.
Fibrosis (3) · Liver Diseases (3) · Liver Failure, Acute (3) · Hepatic Encephalopathy (2) · Hepatitis, Alcoholic (2) · Liver Failure (2) · Ascites (1) · Bacterial Infections (1) · Brain Diseases (1) · Hepatitis B (1) · Hepatorenal Syndrome (1) · Kidney Diseases (1) · Liver Cirrhosis (1) · Liver Cirrhosis, Alcoholic (1)
Digestive System Diseases (24) · Hepatic Insufficiency (24) · Liver Failure (22) · Liver Diseases (21) · Liver Failure, Acute (21) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Central Nervous System Diseases (3) · Hepatitis (3) · Nervous System Diseases (3) · Alcohol-Induced Disorders (2) · Alcohol-Related Disorders (2) · Brain Diseases (2) · Brain Diseases, Metabolic (2) · Chemically-Induced Disorders (2)
Injections (2) · ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (2) · Control Groups (1) · Drug Delivery Systems (1) · Enoxaparin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Prednisone (1) · Rifaximin (1) · Serum Albumin, Human (1) · entecavir (1) · nitazoxanide (1)
Genfit (3) · Cellaion SA (2) · Institute of Liver and Biliary Sciences, India (2) · Akaza Bioscience Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing 302 Hospital (1) · Beijing Continent Pharmaceutical Co, Ltd. (1) · European Foundation for Study of Chronic Liver Failure (1) · GuangZhou Cellgenes Biotechnology Co., Ltd. (1) · HLB Cell Co., Ltd. (1) · Hai Li (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · National Engineering Center of Cell Products (1) · RHEACELL GmbH & Co. KG (1) · Shenzhen Third People's Hospital (1)
China (8) · France (6) · Germany (4) · Spain (4) · Belgium (3) · Italy (3) · United Kingdom (3) · United States (3) · India (2) · Austria (1) · Bulgaria (1) · Denmark (1) · Estonia (1) · Georgia (1) · Hungary (1)
Dong Hyun Sinn, MD, Ph.D (1) · Dr. Shiv Kumar Sarin, DM (1) · Hai Li (1) · Lin B Liang, MD (1) · Matthias Ebert, Prof. Dr. (1) · Ming Shi, PhD (1) · Victor Vargas, MD (1)
2025 (1)